ABBV-295 vs cagrilintide/semaglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Amylin receptor · full Obesity pipeline
ABBV-295
Developed by AbbVie under a licence from Gubra
NCT06144684 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Safety - Adverse Events (AE) incidence" (with 2 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: December 2026 · NCT07514260 (registry estimate)
Reported efficacy
Safety - Adverse Events (AE) incidence (from baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C); Safety - changes in vital signs (from baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C); Safety - Safety laboratory parameters (From baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C): Two-part first-in-human phase 1 study of subcutaneous ABBV-295, a long-acting amylin analog: ABBV-295 demonstrated a favorable tolerability profile at all evaluated dose levels and no serious adverse events were reported. Treatment showed clinically meaningful body weight reduction from -7.75% to -9.79% (least-squares mean) at week 12 with weekly dosing. (not_applicable)
Result source: NCT06144684
cagrilintide/semaglutide · CagriSema
Developed by Novo Nordisk
NCT05394519 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo-controlled trial in 1,200 patients using percentage body weight change, the standard efficacy measure for obesity treatment. CagriSema reduced body weight by 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (p<0.001), meeting the primary endpoint.
Next expected readout: March 2027 · NCT07011667 (registry estimate)
Reported efficacy
Relative change in body weight (From baseline (week 0) to end of treatment (week 68)); Achievement of greater than or equal to (≥) 5% weight reduction (From baseline (week 0) to end of treatment (week 68)): Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001) (met)
Result source: NCT05394519
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ABBV-295 | cagrilintide/semaglutide |
|---|---|---|
| Body weight, % change | —Not reported | -13.7% vs -3.4%a−10.3 vs placeboNCT053945191 other result
|
| Weight loss of 5% or more | —Not reported | —Not posted · NCT05996848 |
| Weight loss of 10% or more | —Not reported | —Not posted · NCT05996848 |
| Waist circumference, change (cm) | —Not reported | —Not posted · NCT05996848 |
Body weight, % change
- ABBV-295
- —Not reported
- cagrilintide/semaglutide
- -13.7% vs -3.4%a−10.3 vs placeboNCT05394519
1 other result
- -18.4% vs -11.9% NCT05813925
Weight loss of 5% or more
- ABBV-295
- —Not reported
- cagrilintide/semaglutide
- —Not posted · NCT05996848
Weight loss of 10% or more
- ABBV-295
- —Not reported
- cagrilintide/semaglutide
- —Not posted · NCT05996848
Waist circumference, change (cm)
- ABBV-295
- —Not reported
- cagrilintide/semaglutide
- —Not posted · NCT05996848
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ABBV-295: no structured comparison results are available for Obesity.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
cagrilintide/semaglutide
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABBV-295's landscape · cagrilintide/semaglutide's landscape